← Back to Screener
Avalon GloboCare Corp. Common Stock (ALBT)
Price$0.49
Favorite Metrics
Price vs S&P 500 (26W)-88.88%
Price vs S&P 500 (4W)-30.72%
Market Capitalization$78,816
All Metrics
Book Value / Share (Quarterly)$1.90
P/TBV (Annual)0.77x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-1.38%
Cash Flow / Share (Quarterly)$-1.03
Price vs S&P 500 (YTD)-66.72%
Gross Margin (TTM)25.70%
Net Profit Margin (TTM)-1355.20%
EPS (TTM)$-9.85
10-Day Avg Trading Volume3.09M
EPS Excl Extra (TTM)$-9.85
Revenue Growth (5Y)-2.97%
EPS (Annual)$-8.44
ROI (Annual)-52.93%
Gross Margin (Annual)15.41%
Net Profit Margin (5Y Avg)-898.04%
Cash / Share (Quarterly)$0.02
Revenue Growth QoQ (YoY)1.43%
ROA (Last FY)-37.66%
Revenue Growth TTM (YoY)6.66%
EBITD / Share (TTM)$-7.43
ROE (5Y Avg)-209.56%
Operating Margin (TTM)-1217.46%
Cash Flow / Share (Annual)$-1.03
P/B Ratio0.01x
P/B Ratio (Quarterly)0.59x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)0.65x
Net Interest Coverage (TTM)-1.72x
ROA (TTM)-155.36%
EPS Incl Extra (Annual)$-8.44
Current Ratio (Annual)0.11x
Quick Ratio (Quarterly)0.09x
3-Month Avg Trading Volume4.94M
52-Week Price Return-88.49%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.46
P/S Ratio (Annual)0.06x
Asset Turnover (Annual)0.06x
52-Week High$5.25
Operating Margin (5Y Avg)-787.76%
EPS Excl Extra (Annual)$-8.44
Tangible BV CAGR (5Y)12.07%
26-Week Price Return-80.13%
Quick Ratio (Annual)0.09x
13-Week Price Return-59.91%
Total Debt / Equity (Annual)0.10x
Current Ratio (Quarterly)0.11x
Enterprise Value$0.904
Revenue / Share Growth (5Y)133.29%
Asset Turnover (TTM)0.11x
Book Value / Share Growth (5Y)-0.05%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-592.72%
Cash / Share (Annual)$0.02
3-Month Return Std Dev273.45%
Gross Margin (5Y Avg)22.93%
Net Income / Employee (TTM)$-4
ROE (Last FY)-111.27%
Net Interest Coverage (Annual)-9.71x
EPS Basic Excl Extra (Annual)$-8.44
Receivables Turnover (TTM)16.92x
Total Debt / Equity (Quarterly)0.10x
EPS Incl Extra (TTM)$-9.85
Receivables Turnover (Annual)9.58x
ROI (TTM)-56.48%
P/S Ratio (TTM)0.06x
Pretax Margin (5Y Avg)-898.04%
Revenue / Share (Annual)$1.42
Tangible BV / Share (Annual)$1.46
Price vs S&P 500 (52W)-123.58%
Year-to-Date Return-62.58%
5-Day Price Return3.46%
EPS Normalized (Annual)$-8.44
ROA (5Y Avg)-78.06%
Net Profit Margin (Annual)-592.72%
Month-to-Date Return-15.44%
Cash Flow / Share (TTM)$-0.90
EBITD / Share (Annual)$-5.33
Operating Margin (Annual)-432.47%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-109.11%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-9.85
P/TBV (Quarterly)0.77x
P/B Ratio (Annual)0.59x
Inventory Turnover (TTM)78.67x
Pretax Margin (TTM)-1355.20%
Book Value / Share (Annual)$1.90
Price vs S&P 500 (13W)-62.78%
Beta0.04x
Revenue / Share (TTM)$0.34
ROE (TTM)-137.60%
52-Week Low$0.34
Industry Peers — Computer Programming(30)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
ALBTAvalon GloboCare Corp. Common Stock | 0.06x | 6.66% | 25.70% | -1217.46% | $0.49 |
CTSHCognizant Technology Solutions | 1.36x | 6.95% | 33.72% | 16.06% | $60.26 |
VRSNVeriSign Inc | 15.34x | 6.37% | 88.15% | 67.67% | $275.81 |
WITWipro Limited | 2.37x | 3.97% | 29.16% | 16.33% | $2.14 |
ZSZscaler, Inc. Common Stock | 6.68x | 23.91% | 76.56% | -4.86% | $134.80 |
DOXAmdocs Limited | 1.57x | -5.98% | 37.61% | 16.15% | $66.96 |
EPAMEPAM SYSTEMS, INC. | 1.28x | 15.42% | 28.88% | 9.53% | $131.90 |
RGTIRigetti Computing, Inc. Common Stock | 928.32x | -34.31% | 29.12% | -1194.41% | $19.64 |
FORTYFormula Systems 1985 Ltd | 0.73x | 5.28% | 22.12% | 8.08% | $128.81 |
COMPCompass, Inc. | 0.88x | 23.67% | 18.41% | -0.91% | $8.08 |
DOCSDoximity, Inc. | 7.16x | 15.92% | 89.75% | 37.44% | $24.39 |
About
Avalon Globocare Corp operates two primary segments: real property management, which is the primary revenue source, and laboratory testing services. The company develops diagnostic and therapeutic biotechnology solutions targeting early detection and treatment of cancers, including oral, ovarian, and kidney variants, as well as skin regeneration, anti-fibrosis, and degenerative disorder applications.